Alpha Tau Treats First Immunocompromised Patient in ADMIRE Study for Recurrent Skin Cancer — Alpha Tau Medical Ltd.

Event summary

Alpha Tau Medical successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) in its ADMIRE study at Banner MD Anderson Cancer Center on July 15, 2026.
The ADMIRE study is evaluating intratumoral Alpha DaRT for immunocompromised patients with recurrent cSCC, a population often excluded from clinical trials due to higher risks and limited treatment options.
Immunocompromised patients face a 65- to 100-fold higher incidence of cSCC compared to the general population, particularly organ transplant recipients.
The study aims to enroll up to 28 patients across 8 sites in the United States, with primary endpoints focused on objective response rate (ORR) and secondary endpoints including progression-free survival and overall survival.

The big picture

Alpha Tau's ADMIRE study addresses a critical gap in treatment options for immunocompromised patients with recurrent cSCC, who often face higher risks and fewer alternatives due to standard therapies' potential to trigger organ rejection or other complications. This strategic focus on underserved populations aligns with broader industry trends toward personalized and targeted cancer therapies, particularly for patients with limited treatment options.

What we're watching

Clinical Trial Progress: The pace at which Alpha Tau enrolls and treats patients in the ADMIRE study will determine its ability to demonstrate the efficacy of Alpha DaRT in immunocompromised populations.
Regulatory Pathway: Whether Alpha Tau can leverage positive data from the ADMIRE study to secure regulatory approvals for broader use of Alpha DaRT in immunocompromised patients with recurrent cSCC.
Market Differentiation: How Alpha Tau's focus on treating historically excluded and vulnerable patient populations will position it against competitors in the cancer therapy space.